We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Group A Streptococcus Rapid Immunoassay Evaluated

By LabMedica International staff writers
Posted on 27 Apr 2016
Clinical reasoning utilizing certain symptoms and scores has not proven to be a reliable decision-making tool to determine whether or not to suspect a group A Streptococcus (GAS) infection in the patient presenting with a sore throat.

An excellent solution for this dilemma would be a bedside rapid antigen detection test (RADT) for GAS that provides a positive or negative result within five to 10 minutes, thus directly influencing the treatment decision. More...
Such RADTs have been evaluated previously using throat culture as the gold standard and initially showed insufficient sensitivity and specificity.

Scientists at North West Hospital and Health Service (Mount Isa, QLD, Australia) collected throat swab samples from patients attending the Mount Isa Hospital emergency department for a sore throat; these samples were compared to swab samples collected from healthy controls that did not have a sore throat and both groups were aged three to 15 years. None of these children had previously had rheumatic fever.

The study team processed the swabs within 72 hours using the Alere Test Pack +Plus with OBC Strep A kit (Alere, Waltham, MA, USA). This test kit had shown a 95% to 97% sensitivity and a specificity of 95% to 100% to detect GAS. In this study the outcomes were compared with the assumption that the sensitivity of the point-of-care test was 95% and with the assumption that the sensitivity was 97%. The treating clinician was blinded to the point-of-care test result.

From June 30, 2014 to February 27, 2015, 248 throat swabs were collected and examined within 72 hours. Out of the 101 patients presenting with a sore throat, 26 (26%) tested positive for GAS. Only one (0.7%) of the 147 control patients had a positive test result. Statistical analysis showed both the positive and negative etiologic predictive value (EPV) to be high. The 95% confidence interval for positive EPV was 88% to 100% and for negative EPV was 97% to 99%, depending on assumptions made.

The authors concluded that their study demonstrated that the point-of-care test Alere Test Pack +Plus Strep A has a high positive predictive value and was able to rule in GAS infection as long as the proportion of carriers is low. Also the negative predictive value for ruling out GAS as the etiologic agent is very high irrespective of the carrier rate. Hence, this test is always useful to rule out GAS infection. The study was published in the April 2016 issue of the International Journal of Infectious Diseases.

Related Links:
North West Hospital and Health Service
Alere

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.